Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at ASM MICROBE 2017 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forge-therapeutics-and-evotec-present-first-efficacy-data-for-lpxc-inhibitor-in-uti-model-at–asm-microbe-2017-5461